AAL

AstraZeneca Revises Vaccine Efficacy Rate, Stock Inches Higher

Short sellers have been coming out in droves lately

Digital Content Manager
Mar 25, 2021 at 10:07 AM
facebook X logo linkedin


The shares of AstraZeneca plc (NASDAQ:AZN) have seen a lot of movement lately, with the drugmaker's Covid-19 vaccine popping up in the news almost daily. Once again, the security is making headlines today, after announcing that previous claims that its vaccine was 79% effective against protecting patients from coronavirus symptoms during its phase three trial were incorrect, and that the vaccine actually has a 76% efficacy rate. The security is attempting to brush off this gaff, and was last seen up 0.3% to trade at $48.89.

As we mentioned, it's been bumpy road for AZN during the past year. While Monday's news allowed the equity to briefly top its 80-day moving average -- a trendline that's more or less kept a lid on shares since last September -- the takeover was brief, and now the equity is struggling just below its year-to-date breakeven, though it still sports a year-over-year lead of around 21%. 

Amid all the chaos, short sellers have been piling on AZN, with short interest up 30.9% in the last two reporting periods. There's still plenty of room on this bearish bandwagon, however, as the 86.28 million shares sold short make up just 3.3% of AZN's available float. 

 

 

Same-Day Trading Power: +227% YTD and Counting  — Get in for $10!

We're celebrating 44 years of helping traders win, and you can now tap into one of our most explosive services — Dynamite Day Trading Signals — for just $10.

This service was built for one thing: capturing intraday gains with precision. 

Access two highly-vetted options trades each week -  Complete with defined entries, exits, and a clear plan for same-day profits.

👉 Click Here to Learn More and Position Yourself to Take Action When the Next Alert Hits.